Cryptotanshinone Inhibits Bladder Cancer Cell Malignant Progression in a Lipopolysaccharide-Induced Inflammatory Microenvironment through NLRP3 Inhibition

Table 1

Association of NLRP3 levels with clinicopathological features from 62 bladder cancer patients.

Variables	N	Strong; expression; n (%)	Moderate expression; n (%)	Weak/negative expression; n (%)	P-value
Sex
Male	45	12 (26.67)	15 (33.33)	18 (40.00)	0.753
Female	17	5 (29.41)	4 (23.53)	8 (47.06)	—
Age (years)
<68	31	9 (29.04)	11 (35.48)	11 (35.48)	0.563
≥68	31	8 (25.81)	8 (25.81)	15 (48.38)	—
Tumorigenesis frequency
Primary	44	10 (22.73)	13 (29.54)	21 (47.73)	0.288
Recurrence	18	7 (38.89)	6 (33.33)	5 (27.78)	—
Tumor number
Unicity	28	7 (25.00)	10 (35.71)	11 (39.29)	0.733
Multiplicity	34	10 (29.41)	9 (26.47)	15 (44.12)	—
Tumor diameter
≤2 cm	33	5 (15.15)	10 (30.30)	18 (54.55)	0.038
>2 cm	29	12 (41.38)	9 (31.03)	8 (27.59)	—
Invasive type
NMIBC	38	6 (15.79)	14 (36.84)	18 (47.37)	0.034
MIBC	24	11 (45.84)	5 (20.83)	8 (33.33)	—
Metastasis
Yes	17	9 (52.94)	5 (29.41)	3 (17.65)	0.012
No	45	8 (17.78)	14 (31.11)	23 (51.11)	—
Histological grade
High	36	11 (30.56)	10 (27.78)	15 (41.66)	0.764
Low	26	6 (23.08)	9 (34.61)	11 (42.31)	—
Smoking
Yes	27	7 (25.93)	8 (29.63)	12 (44.44)	0.939
No	35	10 (28.57)	11 (31.43)	14 (40.00)	—
Drinking
Yes	25	4 (16.00)	8 (32.00)	13 (52.00)	0.220
No	37	13 (35.14)	11 (29.72)	13 (35.14)	—
Hypertension
Yes	33	11 (33.33)	10 (30.30)	12 (36.37)	0.490
No	29	6 (20.69)	9 (31.03)	14 (48.28)	—
Diabetes
Yes	15	6 (40.00)	5 (33.33)	4 (26.67)	0.318
No	47	11 (23.40)	14 (29.79)	22 (46.81)	—
Body mass index (kg/m^2)
<24	31	8 (25.80)	10 (32.26)	13 (41.94)	0.946
≥24	31	9 (29.03)	9 (29.03)	13 (41.94)	—

NMIBC, nonmuscle-invasive bladder cancer; MIBC, muscle-invasive bladder cancer.